Biography and Research Information
OverviewAI-generated summary
A. Chalamalla's research focuses on the pharmacokinetics of CFTR modulators, particularly in the context of cystic fibrosis treatment. Recent publications investigate drug concentrations and their impact on clinical response, exploring how factors like concurrent medication and dietary composition influence drug levels. Chalamalla also employs machine learning approaches to predict average drug concentrations using sparse sampling, evaluating the efficacy of single and multiple time points for such predictions.
This work contributes to understanding variability in treatment response and optimizing drug regimens for individuals with cystic fibrosis. Collaborations include extensive work with Jennifer S. Guimbellot. Chalamalla has published 18 papers with a total of 14 citations and an h-index of 2.
Metrics
- h-index: 2
- Publications: 18
- Citations: 15
Selected Publications
-
Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy (2026)
-
One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators (2025)
Collaboration Network
Top Collaborators
Jennifer S. Guimbellot
University of Arkansas Medical Center
13 shared publications
In database
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- Pilot and feasibility study of dietary composition with elexacaftor‐tezacaftor‐ivacaftor concentrations in people with cystic fibrosis
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant
Showing 5 of 13 shared publications
Kevin J. Ryan
University of Alabama at Birmingham (US)
7 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- Pilot and feasibility study of dietary composition with elexacaftor‐tezacaftor‐ivacaftor concentrations in people with cystic fibrosis
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant
Showing 5 of 7 shared publications
Saly Abouelenein
University of Arkansas for Medical Sciences (US)
6 shared publications
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- 487 Single-sample prediction of average drug concentration in ETI therapy using supervised machine learning
Showing 5 of 6 shared publications
Elizabeth Baker
University of Alabama at Birmingham (US)
5 shared publications
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant
- 865 Elexacaftor/tezacaftor/ivacaftor concentrations are similar in transplanted and non-transplanted people with CF
- Assessing dietary patterns and composition among adults with cystic fibrosis taking modulator therapy
- EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis
Kathleen J. Ramos
University of Washington (US)
5 shared publications
- Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
J Bergeron
University of Alabama at Birmingham (US)
4 shared publications
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant
- 865 Elexacaftor/tezacaftor/ivacaftor concentrations are similar in transplanted and non-transplanted people with CF
Natalie R. Rose
University of Alabama at Birmingham (US)
4 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Pilot and feasibility study of dietary composition with elexacaftor‐tezacaftor‐ivacaftor concentrations in people with cystic fibrosis
- 608 Assessing dietary patterns and composition in adults with cystic fibrosis receiving modulator therapy
- Assessing dietary patterns and composition among adults with cystic fibrosis taking modulator therapy
Edward P. Acosta
4 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Pilot and feasibility study of dietary composition with elexacaftor‐tezacaftor‐ivacaftor concentrations in people with cystic fibrosis
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- 487 Single-sample prediction of average drug concentration in ETI therapy using supervised machine learning
Justin D. Anderson
University of Alabama at Birmingham (US)
3 shared publications
- Pilot and feasibility study of dietary composition with elexacaftor‐tezacaftor‐ivacaftor concentrations in people with cystic fibrosis
- Diet Composition and Elexacaftor-Tezacaftor-Ivacaftor Concentrations in People With Cystic Fibrosis
- Assessing dietary patterns and composition among adults with cystic fibrosis taking modulator therapy
J. Guimbellot
3 shared publications
- 608 Assessing dietary patterns and composition in adults with cystic fibrosis receiving modulator therapy
- EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis
- 487 Single-sample prediction of average drug concentration in ETI therapy using supervised machine learning
Bryan Garcia
2 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
Stefanie Krick
Cystic Fibrosis Foundation (US)
2 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
D. Schellhase
Levine Children's Hospital (US)
2 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
A. Dowell
2 shared publications
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- 865 Elexacaftor/tezacaftor/ivacaftor concentrations are similar in transplanted and non-transplanted people with CF
E. Acosta
2 shared publications
- 425 Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- 865 Elexacaftor/tezacaftor/ivacaftor concentrations are similar in transplanted and non-transplanted people with CF
Similar Researchers
Based on overlapping research topics
Alicia Racelis
University of Arkansas at Fayetteville
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Health and Medical Research Impacts
Anas Alshwayat
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Machine Learning Applications
J.S. Guimbellot
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Health and Medical Research Impacts
Kristin Ashby
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Machine Learning Applications
Eddie Dunn
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Health and Medical Research Impacts
Michelle Hernandez
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Health and Medical Research Impacts